Ann: Cynata Extends FUJIFILM Licence Option in GvHD, page-221

Could I suggest, in this divided and troubled world that we live in, that this debate (if that's the correct word), should end here.
It benefits no one and reduces what could be an interesting chat about different technologies to the level of the playground.
There is room in the world for many different approaches to regenerative medicine and certainly room for our two companies.
We should be supporting each other, investors in these companies are on the same side, not competitors.
MSB has an enviable technology that we should support, as does CYP. Here endeth the lesson.